Nima Emami
Research Subjects
Research Interests
Nima Emami has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Ali Jangjoo
Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
1 shared publication - Amin Saberi
Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany
1 shared publication - Mahdi Mottaghi
Institute for Medical Research Veteran Affairs Medical System Durham North Carolina USA
1 shared publication - Moniba Bijari
Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad 9177948564, Iran
1 shared publication - Roya Moallem
Student Research Committee
1 shared publication - Sara Jangjoo
Student Research Committee
1 shared publication
Latest Publications
- Open Access
- 26 July 2021
- Published by Wiley in International Journal of Endocrinology
- Vol. 2021, 1-14
The Accuracy of Visceral Adiposity Index for the Screening of Metabolic Syndrome: A Systematic Review and Meta-Analysis
Background and Aims. Visceral adiposity index (VAI) is a novel marker of fat distribution and function which incorporates both anthropometric and laboratory measures. Recently, several studies have suggested VAI as a screening tool for metabolic syndrome (MetS). Here, we aimed to consolidate the results of these studies by performing a systematic review and meta-analysis. Methods and Results. We searched PubMed and EMBASE online databases for eligible studies that investigated the association of VAI and MetS. After reviewing 294 records, we included 33 eligible papers with a sum of 20516 MetS and 53242 healthy participants. The risk of bias in the included studies was assessed, and the relevant data was extracted. All included studies reported a significant association between VAI and MetS screening, but were highly heterogeneous in their reported effects. We pooled the diagnostic test accuracy metrics of VAI for MetS screening and showed that it has a moderate-to-high accuracy with an area under the summary receiver operating characteristics curve of 0.847, a pooled sensitivity of 78, and a pooled specificity of 79. Besides, we pooled the difference in means of VAI between patients with MetS and healthy controls, revealing that VAI was 2.15 units higher in MetS patients. Conclusions. VAI is an accurate, low-cost, and widely available screening marker for MetS. However, further studies are needed to evaluate its applicability in clinical practice, determine an optimal cut-off, and identify populations that would benefit the most from it.
- 26 July 2021
- Published by Wiley in International Journal of Endocrinology
- Vol. 2021, 1-14
Open AccessThe Accuracy of Visceral Adiposity Index for the Screening of Metabolic Syndrome: A Systematic Review and Meta-Analysis
Background and Aims. Visceral adiposity index (VAI) is a novel marker of fat distribution and function which incorporates both anthropometric and laboratory measures. Recently, several studies have suggested VAI as a screening tool for metabolic syndrome (MetS). Here, we aimed to consolidate the results of these studies by performing a systematic review and meta-analysis. Methods and Results. We searched PubMed and EMBASE online databases for eligible studies that investigated the association of VAI and MetS. After reviewing 294 records, we included 33 eligible papers with a sum of 20516 MetS and 53242 healthy participants. The risk of bias in the included studies was assessed, and the relevant data was extracted. All included studies reported a significant association between VAI and MetS screening, but were highly heterogeneous in their reported effects. We pooled the diagnostic test accuracy metrics of VAI for MetS screening and showed that it has a moderate-to-high accuracy with an area under the summary receiver operating characteristics curve of 0.847, a pooled sensitivity of 78, and a pooled specificity of 79. Besides, we pooled the difference in means of VAI between patients with MetS and healthy controls, revealing that VAI was 2.15 units higher in MetS patients. Conclusions. VAI is an accurate, low-cost, and widely available screening marker for MetS. However, further studies are needed to evaluate its applicability in clinical practice, determine an optimal cut-off, and identify populations that would benefit the most from it.